Cover Image
市場調查報告書

照護現場 (POC) 的分子診斷市場與潛在性

The Market and Potential for Molecular Point of Care Diagnostics

出版商 Kalorama Information 商品編碼 296895
出版日期 內容資訊 英文 361 Pages
訂單完成後即時交付
價格
Back to Top
照護現場 (POC) 的分子診斷市場與潛在性 The Market and Potential for Molecular Point of Care Diagnostics
出版日期: 2016年02月26日 內容資訊: 英文 361 Pages
簡介

在全球體外診斷 (IVD) 市場上,在照護現場 (POC) 或患者附近進行的分子診斷,是主要的擴大市場。照護現場 (POC) 的分子診斷,不僅提高在患者附近進行的現有簡易檢驗的靈敏度和特異性,在醫院的加護病房 (CCU) 、診療所,門診病人體檢室,地區醫療點等,照護現場 (POC) 的診斷能力也提升。

本報告提供照護現場 (POC) 的分子診斷市場相關調查分析,主要領域為焦點,提供目前銷售額,市場機會相關的系統性資訊。

第1章 摘要整理

第2章 簡介

第3章 照護現場 (POC) 的分子診斷的發展與應用

  • 簡介
  • 分子診斷的進步
  • 微射流
  • 等溫放大
  • 檢驗的自動化
  • 引物,探針
  • 檢測
  • 次世代定序
  • 分散式檢查的分子平台與產品
  • POC的分子診斷的主要檢驗應用等

第4章 照護現場 (POC) 的分子診斷市場

  • 簡介
  • 分散式分子診斷的投資
  • 主要的產品
  • 呼吸系統感染疾病
  • 婦產科疾病,性病
  • 負擔大的疾病
  • 腸胃感染疾病,院內感染,血流感染
  • 非感染性疾病的檢驗
  • 結論

第5章 企業簡介

  • Abacus Diagnostica
  • Advanced Liquid Logic (Illumina)
  • Ahram Biosystems
  • Akonni Biosystems
  • Alere (Abbott)
  • Amplino
  • Analytik Jena
  • Aquila Diagnostic Systems
  • Atlas Genetics
  • Axxin
  • Becton, Dickinson & Co. (BD)
  • Biocartis
  • Biomeme
  • bioMerieux
  • Canon BioMedical
  • Cepheid
  • Molecular Healthcare-Acquired Infection (HAI) Testing
  • Molecular Sexual Health and Women's Health Testing
  • Molecular Critical Infectious Disease Testing
  • Molecular Oncology Testing
  • Coris BioConcept
  • Coyote Bioscience
  • Curetis
  • DestiNA Genomics
  • Diagnostics For All
  • Diagnostics for the Real World
  • DiaSorin
  • DiAssess
  • DNA Electronics
  • DxNA
  • Eiken Chemical
  • Enigma Diagnostics
  • Entopsis
  • Epistem
  • ERBA Molecular (Lumora)
  • Espira
  • GenapSys
  • GeneFluidics
  • GenePOC
  • GeneReach Biotechnology
  • GnuBIO (Bio-Rad)
  • Great Basin Scientific
  • Greiner Bio-One
  • Hai Kang Life
  • Hain Lifescience
  • HiberGene Diagnsotics
  • iCubate
  • Immunexpress
  • InSilixa
  • Lucigen
  • Mast Group
  • MBio Diagnostics
  • Meridian Bioscience
  • Mesa Biotech
  • Metaara Medical Technologies
  • Micronics (Sony)
  • Molbio Diagnostics
  • MP Biomedicals
  • MycroLab Diagnostics
  • Nanobiosym
  • NanoBioSys
  • NanoDetection Technology
  • NanoIVD
  • Nanomix
  • Nanosphere
  • OptiGene
  • Orion Diagnostica
  • Oxford Nanopore Technologies
  • PositiveID
  • PreTect
  • QIAGEN
  • HPV
  • 其他的活動 (開發、許可證、投資)
  • QuantuMDX
  • Quidel
  • Rheonix
  • Roche Diagnostics
  • Scanogen
  • Seegene
  • Spartan Bioscience
  • STAT-Diagnostica
  • T2 Biosystems
  • Thermal Gradient
  • Ubiquitome
  • Ustar Biotechnologies
  • Veredus Laboratories
  • Wave 80 Biosciences
  • Xagenic

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: KLI5916011

Among the various technologies and products of the global in vitro diagnostics (IVD) market, molecular diagnostics performed at the point of care or near the patient are regarded as a leading expansion market. Molecular point-of-care (POC) diagnostics are able to improve the sensitivity and specificity of existing near-patient and rapid tests and also expand the diagnostic capabilities at points of care such as hospital critical care units, physician offices, outpatient clinics, and community health posts in the developing world. The Market and Potential for Molecular Point of Care Diagnostics examines the major segments of molecular POC diagnostics, exploring in-depth both current sales and market opportunity.

The report provides sales / market opportunity for the molecular POC market for respiratory tract infections, including:

  • Molecular Influenza Test POC Market (2015-2020) - Sales / Market Opportunity
  • Molecular Strep A Test POC Market (2015-2020) - Sales / Market Opportunity
  • Molecular RSV POC Market (2015-2020) - Sales / Market Opportunity
  • Molecular POC Market for Other Respiratory Infections (2015-2020) - Sales / Market Opportunity

The report provides sales / market opportunity for the molecular POC market for women's health and sexual health, including:

  • Molecular CT/NG POC Market (2015-2020) - Sales / Market Opportunity
  • Molecular GBS POC Market (2015-2020) - Sales / Market Opportunity
  • Molecular HPV POC Market (2015-2020) - Sales / Market Opportunity
  • Molecular HSV POC Market (2015-2020) - Sales / Market Opportunity
  • Molecular Vaginitis POC Market (2015-2020) - Sales / Market Opportunity

The report provides sales / market opportunity for the molecular POC market for high-burden diseases, including:

  • Molecular HIV POC Market (2015-2020) - Sales / Market Opportunity
  • Molecular TB POC Market (2015-2020) - Sales / Market Opportunity
  • Molecular Hepatitis POC Market (2015-2020) - Sales / Market Opportunity
  • Molecular Malaria POC Market (2015-2020) - Sales / Market Opportunity
  • Molecular POC Market for Other Tropical and Neglected Diseases (2015-2020) - Sales / Market Opportunity

The report provides sales / market opportunity for the molecular POC market for GI pathogens, HAIs and bloodstream infections, including:

  • Molecular POC Market for GI Pathogens (2015-2020) - Sales / Market Opportunity
  • Molecular POC Market for HAIs (2015-2020) - Sales / Market Opportunity
  • Molecular POC Market for Bloodstream Infections (2015-2020) - Sales / Market Opportunity

The report provides sales / market opportunity for the molecular POC market for non-infectious diseases, including:

  • Molecular POC Market for PGx and Other Genetics Testing (2015-2020) - Sales / Market Opportunity
  • Molecular POC Market for Cancer Testing (2015-2020) - Sales / Market Opportunity

The report has gathered as well data on the following:

  • Investments in Decentralized Molecular Diagnostics Companies (2014-2015)
  • Molecular POC Test Markets for Respiratory Tract Infections, Women's Health and Sexual Health, High-Burden Diseases, GI Pathogens, HAIs, Bloodstream Infections, Pharmacogenetics, Other Genetics, and Cancer Testing (2015-2020)
  • Clinical molecular diagnostics has steadily progressed from research-emergent, highly complex tests performed in few labs to analyzer-integrated and -automated steps from sample preparation through results analysis. The development of real-time PCR (qPCR) profoundly expanded the role of molecular diagnostics in healthcare. Real-time PCR enables quantitative molecular results and has been integral to expanding molecular testing capabilities beyond high-complexity labs. The technology minimizes “hands on” time or user requirements, improves test sensitivity, and speeds up the time to results. In addition to qPCR, molecular diagnostics is performed with isothermal amplification technologies, endpoint detection using microarrays, and nucleic acid sequencing technologies.

The Market and Potential for Molecular Point of Care Diagnostics probes molecular point of care diagnostics developments and applications, including:

  • Selected Isothermal Amplification Methods and Platform Examples
  • Selected Analyzer Platforms for Decentralized and POC Molecular Testing with Image Sensor Detectors (CCD, CMOS)
  • Selected Analyzer Platforms for Decentralized and POC Molecular Testing with Photodiode Detectors
  • Selected Analyzer Platforms for Decentralized and POC Molecular Testing with Electrochemical Detectors
  • Selected Analyzer Platforms for Decentralized and POC Molecular Testing with Immunochromatographic Detection
  • Selected NGS Platforms for Decentralized and POC Sequencing
  • Market-Available Molecular POC Diagnostic Platforms (Vendor, Assay Menu, Planned Assays, Regulatory Status, Procedure Integration, Test Principles)
  • Market-Available Hospital Molecular Diagnostic Platforms (Vendor, Assay Menu, Planned Assays, Regulatory Status, Procedure Integration, Test Principles)
  • Hospital and POC Molecular Diagnostic Platforms in Development (Vendor, Assay Menu, Procedure Integration, Test Principles)
  • Market-Available Molecular Diagnostic Platforms for Emerging Markets and the Developing World (Vendor, Assay Menu, Planned Assays, Regulatory Status, Procedure Integration, Test Principles)
  • Molecular Diagnostic Platforms in Development for Emerging Markets and the Developing World (Vendor, Assay Menu, Procedure Integration, Test Principles)
  • Line Probe Assays and Other Molecular Lateral Flow Test Strips (Vendor, Assay Menu, Planned Assays, Regulatory Status)
  • Potential Entrants into Molecular POC Diagnostics (Vendor, Current Platform[s], Primary Market for Platform, Assay Menu, Applicable Tech)
  • Selected Developmental Molecular POC-Enabling Technologies and Platforms by Vendor

The molecular POC diagnostics market includes sales of clinical IVD systems (tests, consumables and instruments) used outside of central clinical laboratories such as hospital laboratories and reference or independent laboratories. Molecular diagnostics includes tests that detect or interrogate nucleic acid analyte sequences using processes such as nucleic acid amplification, hybridization with oligonucleotide probes, and nucleic acid sequencing.

Profiled companies include those with clinical molecular diagnostic systems applicable to POC testing markets; molecular diagnostic systems applicable to hospital lab molecular testing; development-stage molecular diagnostic systems for decentralized testing; molecular diagnostic products for use primarily in emerging markets of the developing world and for field testing; companies with original equipment manufacturer (OEM) platforms and component technologies that could be featured in the molecular POC diagnostics market; and other companies that have been involved in molecular POC diagnostics through investment, collaborative research or technology development that could allow them to enter the market.

Companies profiled include:

  • Abacus Diagnostica
  • Advanced Liquid Logic (Illumina)
  • Ahram Biosystems
  • Akonni Biosystems
  • Alere (Abbott)
  • Amplino
  • Analytik Jena
  • Aquila Diagnostic Systems
  • Atlas Genetics
  • Axxin
  • Becton, Dickinson & Co. (BD)
  • Biocartis
  • Biomeme
  • bioMérieux
  • Canon BioMedical
  • Cepheid
  • Coris BioConcept
  • Coyote Bioscience
  • Curetis
  • DestiNA Genomics
  • Diagnostics For All
  • Diagnostics for the Real World
  • DiaSorin
  • DiAssess
  • DNA Electronics
  • DxNA
  • Eiken Chemical
  • Enigma Diagnostics
  • Entopsis
  • Epistem
  • ERBA Molecular (Lumora)
  • Espira
  • GenapSys
  • GeneFluidics
  • GenePOC
  • GeneReach Biotechnology
  • GnuBIO (Bio-Rad)
  • Great Basin Scientific
  • Greiner Bio-One
  • Hai Kang Life
  • Hain Lifescience
  • HiberGene Diagnsotics
  • iCubate
  • Immunexpress
  • InSilixa
  • Lucigen
  • Mast Group
  • MBio Diagnostics
  • Meridian Bioscience
  • Mesa Biotech
  • Metaara Medical Technologies
  • Micronics (Sony)
  • Molbio Diagnostics
  • MP Biomedicals
  • MycroLab Diagnostics
  • Nanobiosym
  • NanoBioSys
  • NanoDetection Technology
  • NanoIVD
  • Nanomix
  • Nanosphere
  • OptiGene
  • Orion Diagnostica
  • Oxford Nanopore Technologies
  • PositiveID
  • PreTect
  • QIAGEN
  • QuantuMDX
  • Quidel
  • Rheonix
  • Roche Diagnostics
  • Scanogen
  • Seegene
  • Spartan Bioscience
  • STAT-Diagnostica
  • T2 Biosystems
  • Thermal Gradient
  • Ubiquitome
  • Ustar Biotechnologies
  • Veredus Laboratories
  • Wave 80 Biosciences
  • Xagenic

Table of Contents

ONE: EXECUTIVE SUMMARY

  • Introduction
  • Molecular Point-of-Care Diagnostics Defined
  • Strengths and Weakness of Molecular POC Testing
  • Component Technologies of Molecular POC Diagnostics
  • Microfluidics
  • qPCR
  • Microarrays
  • Isothermal Amplification
  • Test Automation
  • Primers and Probes
  • Detection
  • Next-Generation Sequencing
  • Leading Platforms in Molecular POC Diagnostics
  • Investment in Decentralized Molecular Diagnostics - Venture Financing and Public
  • Offerings (2009-2015)
  • Global Molecular POC Diagnostics Market (2015-2020)
  • Major Conclusions

TWO: INTRODUCTION TO MOLECULAR POINT OF CARE DIAGNOSTICS

  • Introduction
  • Point-of-Care Diagnostics in Brief
  • Common Tests and Analytes in POC Diagnostics
  • Market Drivers for POC Diagnostics
  • Market Barriers for POC Diagnostics
  • Molecular Diagnostics
  • Real-Time PCR (qPCR)
  • Isothermal Amplification Methods
  • Microarrays
  • Sequencing
  • Common Tests and Analytes in Molecular Diagnostics
  • Advantages and Disadvantages of Molecular Diagnostics at the Point of Care
  • Summary

THREE: MOLECULAR POINT OF CARE DIAGNOSTICS DEVELOPMENT AND APPLICATIONS

  • Introduction
  • Advances in Molecular Diagnostics
  • Microfluidics
  • Isothermal Amplification
  • Test Automation
  • Primers and Probes
  • Detection
  • Next-Generation Sequencing
  • Molecular Platforms and Products for Decentralized Testing
  • Major Testing Applications for Molecular POC Diagnostics
  • Influenza
  • Strep A
  • Respiratory Syncytial Virus (RSV)
  • Other Respiratory Infections
  • Chlamydia and Gonorrhea
  • Group B Streptococcus
  • Human Papillomavirus
  • Herpes Simplex Virus
  • Vaginitis
  • Human Immunodeficiency Virus (HIV)
  • Tuberculosis
  • Hepatitis
  • Malaria
  • Other Tropical and Neglected Diseases
  • Gastrointestinal Infections
  • Hospital-Acquired Infections (HAIs)
  • Bloodstream Infections (BSIs)
  • Pharmacogenetics
  • Hereditary Disease
  • Cancer
  • Conclusions

FOUR: MARKETS FOR MOLECULAR POINT-OF-CARE DIAGNOSTICS

  • Introduction
  • Investment in Decentralized Molecular Diagnostics - Venture Financing and Public
  • Offerings (2009-2015)
  • Respiratory Tract Infections
  • Women's Health and Sexual Health
  • High-Burden Diseases
  • Gastrointestinal, Hospital-Acquired and Bloodstream Infections
  • Non-Infectious Disease Tests - Pharmacogenetics, Hereditary Traits and Cancer
  • Conclusions

FIVE: COMPANY PROFILES

  • Abacus Diagnostica
  • Advanced Liquid Logic (Illumina)
  • Ahram Biosystems
  • Akonni Biosystems
  • Alere (Abbott)
  • Amplino
  • Analytik Jena
  • Aquila Diagnostic Systems
  • Atlas Genetics
  • Axxin
  • Becton, Dickinson & Co. (BD)
  • Biocartis
  • Biomeme
  • bioMérieux
  • Canon BioMedical
  • Cepheid
  • Molecular Healthcare-Acquired Infection (HAI) Testing
  • Molecular Sexual Health and Women's Health Testing
  • Molecular Critical Infectious Disease Testing
  • Molecular Oncology Testing
  • Coris BioConcept
  • Coyote Bioscience
  • Curetis
  • DestiNA Genomics
  • Diagnostics For All
  • Diagnostics for the Real World
  • DiaSorin
  • DiAssess
  • DNA Electronics
  • DxNA
  • Eiken Chemical
  • Enigma Diagnostics
  • Entopsis
  • Epistem
  • ERBA Molecular (Lumora)
  • Espira
  • GenapSys
  • GeneFluidics
  • GenePOC
  • GeneReach Biotechnology
  • GnuBIO (Bio-Rad)
  • Great Basin Scientific
  • Greiner Bio-One
  • Hai Kang Life
  • Hain Lifescience
  • HiberGene Diagnsotics
  • iCubate
  • Immunexpress
  • InSilixa
  • Lucigen
  • Mast Group
  • MBio Diagnostics
  • Meridian Bioscience
  • Mesa Biotech
  • Metaara Medical Technologies
  • Micronics (Sony)
  • Molbio Diagnostics
  • MP Biomedicals
  • MycroLab Diagnostics
  • Nanobiosym
  • NanoBioSys
  • NanoDetection Technology
  • NanoIVD
  • Nanomix
  • Nanosphere
  • OptiGene
  • Orion Diagnostica
  • Oxford Nanopore Technologies
  • PositiveID
  • PreTect
  • QIAGEN
  • HPV
  • Other Activities (Development, Licensing, Investment)
  • QuantuMDX
  • Quidel
  • Rheonix
  • Roche Diagnostics
  • Scanogen
  • Seegene
  • Spartan Bioscience
  • STAT-Diagnostica
  • T2 Biosystems
  • Thermal Gradient
  • Ubiquitome
  • Ustar Biotechnologies
  • Veredus Laboratories
  • Wave 80 Biosciences
  • Xagenic

LIST OF EXHIBITS

ONE: EXECUTIVE SUMMARY

  • Table 1-1: Advantages of Point-of-Care Diagnostics by Setting - Hospital POC, POL/Outpatient, Low-Resource and Developing Areas
  • Table 1-2: Disadvantages of Point-of-Care Diagnostics by Setting - Hospital POC, POL/Outpatient, Low-Resource and Developing Areas
  • Table 1-3: Market-Available Molecular POC Diagnostic Platforms (Vendor, Assay Menu, Planned Assays, Regulatory Status, Procedure Integration, Test Principles)
  • Figure 1-1: Investments in Decentralized Molecular Diagnostics Companies (2014-2015)
  • Figure 1-2: Molecular POC Diagnostics Market (2015-2020) ($ millions)

TWO: INTRODUCTION TO MOLECULAR POINT OF CARE DIAGNOSTICS

  • Table 2-1: Advantages of Point-of-Care Diagnostics by Setting - Hospital POC, POL/Outpatient, Low-Resource and Developing Areas
  • Table 2-2: Disadvantages of Point-of-Care Diagnostics by Setting - Hospital POC, POL/Outpatient, Low-Resource and Developing Areas
  • Table 2-3: Selected Isothermal Amplification Methods and Platform Examples

THREE: MOLECULAR POINT OF CARE DIAGNOSTICS DEVELOPMENT AND APPLICATIONS

  • Table 3-1: Selected Isothermal Amplification Methods and Platform Examples
  • Table 3-2: Selected Analyzer Platforms for Decentralized and POC Molecular Testing with Image Sensor Detectors (CCD, CMOS)
  • Table 3-3: Selected Analyzer Platforms for Decentralized and POC Molecular Testing with Photodiode Detectors
  • Table 3-4: Selected Analyzer Platforms for Decentralized and POC Molecular Testing with Electrochemical Detectors
  • Table 3-5: Selected Analyzer Platforms for Decentralized and POC Molecular Testing with Immunochromatographic Detection
  • Table 3-6: Selected NGS Platforms for Decentralized and POC Sequencing
  • Table 3-7: Market-Available Molecular POC Diagnostic Platforms (Vendor, Assay Menu, Planned Assays, Regulatory Status, Procedure Integration, Test Principles)
  • Table 3-8: Market-Available Hospital Molecular Diagnostic Platforms (Vendor, Assay Menu, Planned Assays, Regulatory Status, Procedure Integration, Test Principles)
  • Table 3-9: Hospital and POC Molecular Diagnostic Platforms in Development (Vendor, Assay Menu, Procedure Integration, Test Principles)
  • Table 3-10: Market-Available Molecular Diagnostic Platforms for Emerging Markets and the Developing World (Vendor, Assay Menu, Planned Assays, Regulatory Status, Procedure Integration, Test Principles)
  • Table 3-11: Molecular Diagnostic Platforms in Development for Emerging Markets and the Developing World (Vendor, Assay Menu, Procedure Integration, Test Principles)
  • Table 3-12: Line Probe Assays and Other Molecular Lateral Flow Test Strips (Vendor, Assay Menu, Planned Assays, Regulatory Status)
  • Table 3-13: Potential Entrants into Molecular POC Diagnostics (Vendor, Current Platform[s], Primary Market for Platform, Assay Menu, Applicable Tech)
  • Table 3-14: Selected Developmental Molecular POC-Enabling Technologies and Platforms by Vendor

FOUR: MARKETS FOR MOLECULAR POINT-OF-CARE DIAGNOSTICS

  • Figure 4-1: Investments in Decentralized Molecular Diagnostics Companies (2014-2015)
  • Table 4-1: Investments in Decentralized Molecular Diagnostics Companies (2014-2015)
  • Figure 4-2: Molecular Influenza Test POC Market (2015-2020) ($ millions) - Sales / Market Opportunity
  • Figure 4-3: Molecular Strep A Test POC Market (2015-2020) ($ millions) - Sales / Market Opportunity
  • Figure 4-4: Molecular RSV POC Market (2015-2020) - Sales / Market Opportunity
  • Figure 4-5: Molecular POC Market for Other Respiratory Infections (2015-2020) - Sales / Market Opportunity
  • Table 4-2: Molecular POC Market for Respiratory Tract Infections - Influenza, Strep A, RSV, Others (2015-2020) - Sales / Market Opportunity
  • Figure 4-6: Molecular CT/NG POC Market (2015-2020) - Sales / Market Opportunity
  • Figure 4-7: Molecular GBS POC Market (2015-2020) - Sales / Market Opportunity ... 142
  • Figure 4-8: Molecular HPV POC Market (2015-2020) - Sales / Market Opportunity .. 144
  • Figure 4-9: Molecular HSV POC Market (2015-2020) - Sales / Market Opportunity ... 146
  • Figure 4-10: Molecular Vaginitis POC Market (2015-2020) - Sales / Market Opportunity
  • Table 4-3: Molecular POC Market for Women's Health and Sexual Health - CT/NG, GBS, HPV, HSV, Vaginitis (including TV) (2015-2020) - Sales / Market Opportunity
  • Figure 4-11: Molecular HIV POC Market (2015-2020) - Sales / Market Opportunity . 152
  • Figure 4-12: Molecular TB POC Market (2015-2020) - Sales / Market Opportunity
  • Figure 4-13: Molecular Hepatitis POC Market (2015-2020) - Sales / Market Opportunity
  • Figure 4-14: Molecular Malaria POC Market (2015-2020) - Sales / Market Opportunity
  • Figure 4-15: Molecular POC Market for Other Tropical and Neglected Diseases (2015-2020) - Sales / Market Opportunity
  • Table 4-4: Molecular POC Market for High-Burden Diseases - HIV, TB, Hepatitis, Malaria, Other Tropical and Neglected Diseases (2015-2020) - Sales / Market Opportunity
  • Figure 4-16: Molecular POC Market for GI Pathogens (2015-2020) - Sales / Market Opportunity
  • Figure 4-17: Molecular POC Market for HAIs (2015-2020) - Sales / Market Opportunity
  • Figure 4-18: Molecular POC Market for Bloodstream Infections (2015-2020) - Sales / Market Opportunity
  • Table 4-5: Molecular POC Market for GI Pathogens, HAIs and Bloodstream Infections (2015-2020) - Sales / Market Opportunity
  • Figure 4-19: Molecular POC Market for PGx and Other Genetics Testing (2015-2020) - Sales / Market Opportunity
  • Figure 4-20: Molecular POC Market for Cancer Testing (2015-2020) - Sales / Market Opportunity
  • Table 4-6: Molecular POC Market for Non-Infectious Diseases - Pharmacogenetics / Hereditary Traits and Cancer (2015-2020) - Sales / Market Opportunity
  • Table 4-7: Molecular POC Test Markets for Respiratory Tract Infections, Women's Health and Sexual Health, High-Burden Diseases, GI Pathogens, HAIs, Bloodstream Infections, Pharmacogenetics, Other Genetics, and Cancer Testing (2015-2020) - Sales / Market Opportunity

FIVE: COMPANY PROFILES

  • Table 5-1: Alere Revenue (2012-2015)
  • Table 5-2: Analytik Jena Revenue (FY 2011-2014)
  • Table 5-3: Becton, Dickinson & Co. (BD) Revenue (FY 2012-2015)
  • Table 5-4: Biocartis NV Revenue (2012-2015)
  • Table 5-5: bioMérieux Revenue (2012-2015)
  • Table 5-6: Cepheid Revenue (2012-2015)
  • Table 5-7: DiaSorin Revenue (2012-2015)
  • Table 5-8: Eiken Chemical Revenue (FY 2012-2015)
  • Table 5-9: Epistem Revenue (FY 2012-2015)
  • Table 5-10: Great Basin Corporation Revenue (2012-2015)
  • Table 5-11: Meridian Bioscience Revenue (FY 2012-2015)
  • Table 5-12: Nanosphere Revenue (2012-2015)
  • Table 5-13: Orion Diagnostica Revenue (2012-2015)
  • Table 5-14: PositiveID Revenue (2012-2015)
  • Table 5-15: QIAGEN Revenue (2012-2015)
  • Table 5-16: Quidel Corporation Revenue (2012-2015)
  • Table 5-17: Roche Diagnostics Revenue (2012-2015)
  • Table 5-18: Seegene Revenue (2012-2015)
  • Table 5-19: T2 Biosystems Revenue (FY 2012-FY 2015)
Back to Top